Your session is about to expire
← Back to Search
Radiation therapy followed by mutation-matched TKI treatment for Non-Small Cell Lung Cancer
Study Summary
This trial aims to see if giving radiation to the main lung tumor before starting a specific drug can help patients with advanced lung cancer live longer without their disease getting worse.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are prospective patients still eligible to participate in this ongoing medical study?
"The trial listed on clinicaltrials.gov, initially shared on April 15th, 2024 and last revised on March 5th, 2024, is currently inactive in terms of participant recruitment. Nevertheless, there are a noteworthy total of 2052 other ongoing trials that are presently open for enrollment."
Has the combined approach of radiation therapy followed by mutation-targeted TKI treatment received approval from the FDA?
"Designated as a Phase 2 trial, our team at Power rates the safety of radiation therapy paired with mutation-matched TKI treatment at level 2. This indicates existing data supporting safety but lacking evidence for efficacy."
Share this study with friends
Copy Link
Messenger